Summary Introduction: Acknowledging informed consent and warning of material risk, the present study examined the current debate regarding early discussion of Sudden Unexplained Death in Epilepsy (SUDEP). It sought to confirm the profile of those prone to SUDEP and to determine the basis for disclosure to patients. Methods: Patients with SUDEP attending an Australian outpatient epilepsy clinic between 1985 and 2000 were compared to an age, gender and epilepsy type cross-matched control group to ascertain risk factors for SUDEP and similarities to published parameters. These were evaluated as the basis for actions in negligence for either disclosure or failure to disclose. Results: Twenty-one SUDEP patients were identified: aged 18-70 years; the majority had localisation-related epilepsy (13:8, 62%); male to female ratio was 3:1; and 15/21 used polypharmacy, compared with 8/21 controls (P = 0.02951). Handedness, alcohol use or deterioration of epilepsy were unrelated. Discussion: This population mirrored the literature and confirmed an absence of risk factors amenable to modification. As discussion of SUDEP with males with localisation-related epilepsy on polypharmacy could not alter outcome it is unlikely that failure to disclose could be causal and hence successful in an action for negligence. Conversely, disclosure, in the absence of the patient seeking the information, may causally adversely affect quality of life hence providing successful action in negligence. Duty of care dictates open and frank discussion with those seeking the information. Thus, each case must be managed individually and doctors are advised to document the decision-making process.
Introduction
Modern medicine demands that patients give informed consent [1] [2] [3] to any proposed intervention and imposes upon the clinician a duty to warn patients of material risks [4] [5] [6] [7] to which the patient may be exposed during the course of treatment of a particular illness. A material risk is defined as a risk which, once presented to the patient, would lead an ordinary patient in similar circumstances to either accept or reject the specified intervention. 8, 9 No illness is without risk and no treatment without potential complications but a material risk is one that attaches to a mode of treatment about which the doctor knows, or should know, that the particular patient is likely to rate significant. 9 In recent times there has emerged a debate regarding the obligation to warn even newly diagnosed patients of the risk of Sudden Unexplained Death in Epilepsy (SUDEP). [10] [11] [12] One of the arguments proposed when considering SUDEP is the ''right to know'' but this ignores the converse which is the ''right not to know''. This conflict, whether it be regarding SUDEP or cancer, places the clinician in a serious ethical dilemma because it requires the balancing of these diametrically opposed concepts and demands a value judgement on the part of the clinician. 13 It dictates a serious determination, by that clinician, as to what constitutes a material risk for a given patient. The clinician must ascertain whether advising a patient of SUDEP would overcome a material risk inherent in the treatment of the illness.
It has been established that individuals with epilepsy have an increased risk of death as compared to the general population. [14] [15] [16] [17] The cause of death can be attributed to both the underlying disease or the epilepsy itself [14] [15] [16] [17] with underlying diseases such as neoplasia, cardiovascular or cerebrovascular diseases, accounting for more than 50% of such deaths. 15 The most common category of seizure related death is SUDEP, which has been reported to be associated with between 2 and 17% of all deaths with epilepsy. 18 SUDEP usually occurs unwitnessed and is therefore incompletely documented. The following definition has been proposed by Nashef, ''. . . sudden unexpected, non-traumatic and non-drowning death in an individual with epilepsy with or without evidence for a seizure and excluding documented status epilepticus where post-mortem examination does not reveal a cause for death''. 19 Ficker 18 simplified this definition to be ''. . . the sudden death of a person with epilepsy without reasonable anatomical or toxicological explanation . . . ''. Although several suggestions have been made, the physiological mechanisms underlying SUDEP remain unclear [20] [21] [22] [23] as the majority of deaths occur in the absence of an anatomical or toxicological cause. 24 The objective of this study was to investigate patients with SUDEP in an outpatient clinic and to examine its association with some selected clinical variables. It sought to determine if this population, taken from an Australian outpatient clinic, yielded extra data or mirrored that reported in the literature thereby allowing extrapolation for definition of modifiable risk factors. The purpose of such analysis was to identify possible material risk factors, which may demand disclosure to patients to assist them in ongoing treatment. It also aimed to detect those circumstances which should encourage early discussion of SUDEP with patients so as to satisfy the legal obligation to warn patients without causing them undue alarm.
Materials and methods

Study population
This study was conducted by review of statistics of SUDEP cases encountered in an Australian private practice, community-based, outpatient epilepsy clinic. Records of all cases of SUDEP reported from 1985 to 2000, were reviewed with regard to age, gender, type of epilepsy and use of anti-epileptic medications (AEMs).
All patients attending this clinic are diagnostically coded which enabled selection of a control group. On the basis of comparable age (SUDEP patient's age ±1 year), gender and type of epilepsy with presentation to the clinic within the same time reference period.
Comparisons were made between the two groups for right/left handedness and for the number of anti-epileptic medications taken at the time of death. Statistical analysis was performed to determine clinical significance using the Fisher exact test from the S-Plus Statistical Package.
Those factors catalogued as applicable to SUDEP were then considered for their relevance as material risks demanding discussion with patients. The ethics of such disclosure and the legal implications were evaluated.
Results
Age and gender
Twenty-one cases of SUDEP were identified from the clinic database within the time frame parameters. Their demographics revealed an age range of 18-70 years (mean 45.3 ± 20.5 years). The male to female ratio was approximately three to one (Fig. 1 ).
Type of epilepsy
The patients with SUDEP experienced both generalised and/or localisation related epilepsy--8 with generalised epilepsy and 13 patients with localisation related epilepsy ( Table 1 ). The SUDEP cases demonstrated compliance with therapy and either improved or improving seizure control at the time of death. 
Antiepileptic medication
Fifteen out of the 21 SUDEP patients were on two or three AEMs (Table 1) but there was no evidence that any particular AEM influenced the risk of SUDEP. Of the control patients, only 8 out of 21 were on two or three AEMs which confirmed polypharmacy as a significant risk factor (P = 0.02951).
Right/left handedness
In the SUDEP group, 13 were right handed, 5 were left handed, 2 were ambidextrous and for 1 patient this information was unavailable. In the control group, 15 were right handed, 4 were left handed, with no ambidextrous patients and for two people the information was not reported. The Fisher exact test for these data produced a P value of 0.5987 demonstrating lack of significance (Table 2) .
Other factors
The majority of cases were found dead at home with one drowning incident, which would be excluded according to the definition of Nashef 19 although the cause of death was recorded as SUDEP by the Coroner. No association with alcohol was found. Review of patient records, to determine whether there was deterioration of seizure status or increased seizure frequency at the time of death, failed to demonstrate any such deterioration of seizure control. Hence any exacerbation of the epilepsy or failure of compliance with treatment were excluded as contributing factors to the SUDEP. If anything, the epilepsy seemed better controlled at the time of death, with fewer seizures (not statistically significant) and there was no evidence of medication reduction at the time of death.
Discussion
Various studies have reported that the age group 20-40 years is most susceptible to SUDEP and this study showed a mean of 45.3 ± 20.5 years, which encompasses this age band. 25 The average age of death in the outpatient group examined by Timmings 26 was 35 years with similar results found by Leestma et al. in their work. 27 Fig. 1 demonstrated that there were more deaths in males, a finding that is consistent with the majority of studies. [28] [29] [30] The Rochester study 31 reported more SUDEP among those with localisation-related symptomatic epilepsy but this was not a universal finding in all studies. The recent case-control study by Nilsson et al. found an increased risk of SUDEP among men with idiopathic generalised epilepsy compared with localisation-related symptomatic epilepsy. 30 Patients in this current study suffered from both generalised and localisation related epilepsy with a preponderance of localisation-related epilepsy (13:8, approximately 62%).
Incidence data suggest that the risk of SUDEP is related to seizure control, with higher sudden death rates being found in cohorts with intractable epilepsy. 32 The SUDEP cases in this study demonstrated compliance with therapy and review of the patient records, specifically aimed to determine patient's reported seizure control, demonstrated that the patients' epilepsy had not deteriorated at the time of death.
Although there was no evidence that any particular AEM influenced the risk of SUDEP (Table 1) , polytherapy was found to be a significant risk factor, confirming the refractory nature of the epilepsy. 33 There are anecdotal reports of bradyarrhythmia and sinus arrest being associated with carbamazepine 34 and changes in epilepsy therapy may also increase the risk of SUDEP, perhaps by reflex function. Lip and Brodie 35 found that a recent change in AEMs, mostly involving a dose reduction or drug withdrawal, increased the risk of SUDEP. Dosage reduction or drug withdrawal may suggest that the patients required less medication because of improved clinical status. This view may support the finding that epilepsy did not appear to deteriorate in current SUDEP cases. Treatment had not been significantly altered in these SUDEP patients, with the deaths occurring while patients were on stable medication regimens.
What has emerged from the present study is that the identified population does broadly reflect that which is accepted within the literature. This sample of SUDEP patients, was predominantly male, with mostly localisation-related epilepsy requiring polypharmacy and seizure rates were not increasing at the time of death. Other confounding variables could not be identified. None of these factors are modifiable by practical intervention by the clinician, as they are all characteristics of the patients themselves. It may be argued that advice about SUDEP could be targeted at this particular patient group but it would not alter the therapy offered.
The responsibility of the attending physician to obtain informed consent and satisfy the duty to warn of material risk implies that the actions of the doctor will directly influence outcomes under investigation. [1] [2] [3] 8, 9 The analysis of this patient population, confirmed by the literature, has not identified a causal relationship between that which the physician may do and the outcome of SUDEP. Success in an action for negligence demands the plaintiff establishes a causal relationship between the outcome and actions taken. 36 It follows that failure to discuss SUDEP with a patient with epilepsy cannot constitute grounds for negligence as the outcome cannot be as a consequence of the actions of the doctor based upon current knowledge.
This would appear to remove the basis for litigation against the doctor who chooses not to discuss the topic, especially if that patient has not asked the question. Does it also satisfy the ethical dictates of a proper doctor-patient relationship? The answer to this question requires consideration of the relative risks or benefits from disclosure to the patient who has not enquired about mortality.
Inherent in the above reconfirmed profile of the patient prone to SUDEP is the reaffirmation that no identified form of intervention will alter its propensity. This raises the question, ''What will be gained by warning of that which cannot be prevented and knowledge of which may seriously deteriorate quality of life?'' This in turn raises the question of the patient's right ''not to know''.
Warning of a possible outcome for which no form of intervention is recognised, but knowledge of which may adversely affect quality of life, may actually contravene the basic medical and ethical tenant underlying proper medical care, namely ''do no harm''. The negative influence on quality of life may itself represent a form of negligence. It may be possible to show causal connection between impaired quality of life and the doctor divulging information that the patient did not seek and for which it might be claimed the patient had a right ''not to know''. It could be argued that this disclosure of SUDEP may represent a form of negligence and deny the option of therapeutic privilege. 3 Therapeutic privilege is a unique situation, within medical care, in which it is deemed to be in the patient's best interests for the doctor to withhold information. 3 It is generally applied to the psychiatric setting in which the doctor may deliberately omit information to avoid unnecessary anxiety. This omission to restrict anxiety or fear is justified on the basis that such fear may result in the patient refusing required treatment. 3 The present study reaffirmed polypharmacy as a significant precursor to SUDEP but such polypharmacy, especially within the context of a specialist epilepsy clinic, is provided as a necessary intervention for the epilepsy management. 8/21 (38%) of controls still required polytherapy which may have been refused on the grounds of fear of SUDEP.
This situation is significantly altered if the patient actively seeks information about mortality and epilepsy. 5 In this circumstance the doctor represents the source of information and there exists a duty of care to provide the patient with accurate and informed response to questions raised or alternatively the means by which the patient can discover such information. [4] [5] [6] [7] [8] [9] The present study represents such a source of information as it confirms the notion that SUDEP is essentially unpredictable for any individual patient. It also confirms that the topic of SUDEP involves many moral dilemmas, most of which do not have absolute solutions. The population statistics do not exclude the possibility that a female with generalised epilepsy, successfully treated with a single AEM, may still be subject to SUDEP. It does suggest that this is less likely than the more recognised profile but also reaffirms the medical adage that ''never'' and ''always'' are dangerous terms when used in the doctor-patient relationship. To assure the patient of something which cannot be assured may also represent a form of negligence and failure of duty of care. It is imperative to emphasise that the profile, reaffirmed in this study, represents a population profile but is not universally applicable.
What emerges is the need for a common sense approach to treat each case on its merits, to understand what is established fact and to meet the patient's needs. The ethical consideration is met if the doctor tries to ascertain what the patient wants to know and responds accordingly by providing that information which the patient requests. Where doubt exists, the doctor may actually directly ask the patient questions which encourage the patient to seek additional information. This will vary from patient to patient and it behoves the doctor to document the process undertaken to arrive at the final conclusion of whether or not to disclose the risks of SUDEP.
This documentation will provide a strong defence in the unlikely situation of the doctor being challenged in an action for negligence.
